EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 327 filers reported holding EXELIXIS INC in Q4 2021. The put-call ratio across all filers is 1.44 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $97,733 | +3.3% | 4,472,824 | -9.6% | 0.01% | +7.7% |
| Q2 2023 | $94,573 | -19.0% | 4,948,814 | -17.7% | 0.01% | -23.5% |
| Q1 2023 | $116,710 | +9.8% | 6,012,788 | -9.3% | 0.02% | 0.0% |
| Q4 2022 | $106,312 | -99.9% | 6,627,890 | -17.4% | 0.02% | -19.0% |
| Q3 2022 | $125,802,000 | -55.0% | 8,023,042 | -40.2% | 0.02% | -40.0% |
| Q2 2022 | $279,509,000 | -21.8% | 13,425,015 | -14.9% | 0.04% | -2.8% |
| Q1 2022 | $357,592,000 | +14.4% | 15,773,785 | -7.8% | 0.04% | +28.6% |
| Q4 2021 | $312,587,000 | -14.2% | 17,099,967 | -0.8% | 0.03% | -17.6% |
| Q3 2021 | $364,393,000 | +1.6% | 17,237,135 | -12.4% | 0.03% | +3.0% |
| Q2 2021 | $358,488,000 | -23.5% | 19,675,540 | -5.1% | 0.03% | -29.8% |
| Q1 2021 | $468,389,000 | +32.7% | 20,734,338 | +17.9% | 0.05% | +30.6% |
| Q4 2020 | $353,001,000 | +5.8% | 17,588,494 | +28.9% | 0.04% | -7.7% |
| Q3 2020 | $333,529,000 | +4.3% | 13,641,269 | +1.3% | 0.04% | -2.5% |
| Q2 2020 | $319,639,000 | +67.3% | 13,464,133 | +21.4% | 0.04% | +33.3% |
| Q1 2020 | $191,032,000 | +68.7% | 11,093,611 | +72.6% | 0.03% | +100.0% |
| Q4 2019 | $113,244,000 | -0.6% | 6,426,991 | -0.3% | 0.02% | -6.2% |
| Q3 2019 | $113,984,000 | -13.2% | 6,445,254 | +4.9% | 0.02% | -11.1% |
| Q2 2019 | $131,279,000 | +8.3% | 6,143,165 | +20.7% | 0.02% | 0.0% |
| Q1 2019 | $121,170,000 | +103.3% | 5,091,189 | +68.0% | 0.02% | +80.0% |
| Q4 2018 | $59,596,000 | -2.0% | 3,029,801 | -11.7% | 0.01% | +11.1% |
| Q3 2018 | $60,804,000 | -41.5% | 3,431,376 | -29.0% | 0.01% | -43.8% |
| Q2 2018 | $104,017,000 | -53.5% | 4,833,478 | -52.1% | 0.02% | -55.6% |
| Q1 2018 | $223,689,000 | -18.1% | 10,098,845 | +12.5% | 0.04% | -18.2% |
| Q4 2017 | $272,963,000 | +20.9% | 8,979,035 | -3.6% | 0.04% | +12.8% |
| Q3 2017 | $225,701,000 | +8.8% | 9,314,952 | +10.6% | 0.04% | +5.4% |
| Q2 2017 | $207,352,000 | -6.2% | 8,418,663 | -17.4% | 0.04% | -9.8% |
| Q1 2017 | $220,975,000 | +34.4% | 10,197,283 | -7.5% | 0.04% | +24.2% |
| Q4 2016 | $164,397,000 | +1.5% | 11,025,932 | -12.9% | 0.03% | 0.0% |
| Q3 2016 | $161,954,000 | +33.6% | 12,662,570 | -18.4% | 0.03% | +26.9% |
| Q2 2016 | $121,265,000 | +21.4% | 15,526,930 | -37.8% | 0.03% | +23.8% |
| Q1 2016 | $99,858,000 | -29.3% | 24,964,590 | -0.3% | 0.02% | -30.0% |
| Q4 2015 | $141,215,000 | +2.3% | 25,038,170 | +1.8% | 0.03% | -3.2% |
| Q3 2015 | $138,045,000 | +121.7% | 24,606,910 | +48.6% | 0.03% | +138.5% |
| Q2 2015 | $62,268,000 | +36.8% | 16,560,640 | -6.5% | 0.01% | +44.4% |
| Q1 2015 | $45,514,000 | +70.3% | 17,709,640 | -4.6% | 0.01% | +50.0% |
| Q4 2014 | $26,727,000 | -6.8% | 18,560,450 | -1.0% | 0.01% | 0.0% |
| Q3 2014 | $28,674,000 | -56.2% | 18,741,050 | -2.9% | 0.01% | -57.1% |
| Q2 2014 | $65,411,000 | -4.5% | 19,295,340 | -0.3% | 0.01% | -6.7% |
| Q1 2014 | $68,522,000 | -66.7% | 19,356,410 | -42.4% | 0.02% | -37.5% |
| Q4 2013 | $206,070,000 | +142.3% | 33,616,760 | +130.0% | 0.02% | +14.3% |
| Q3 2013 | $85,059,000 | -39.1% | 14,614,960 | -52.5% | 0.02% | +10.5% |
| Q2 2013 | $139,642,000 | – | 30,758,248 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 15,001,073 | $265,294,000 | 64.62% |
| Sargent Investment Group, LLC | 465,620 | $8,234,000 | 3.70% |
| Orbimed Advisors | 3,912,900 | $69,200,000 | 1.31% |
| Bellevue Group AG | 3,858,700 | $68,241,000 | 1.27% |
| TEALWOOD ASSET MANAGEMENT INC | 137,129 | $2,425,000 | 1.04% |
| CAPITAL MANAGEMENT CORP /VA | 200,995 | $3,555,000 | 0.97% |
| Penn Capital Management Company, LLC | 517,988 | $9,161,000 | 0.96% |
| Chicago Capital, LLC | 801,560 | $14,176,000 | 0.95% |
| Portolan Capital Management | 454,444 | $8,037,000 | 0.91% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 103,534 | $1,830,000 | 0.85% |